Biocryst looks to raise the profile of its factor D inhibitor

Retrieved on: 2021-02-22 15:52:46

Tags for this article:

Click the tags to see associated articles and topics

Biocryst looks to raise the profile of its factor D inhibitor. View article details on hiswai:

Excerpt

But C5 inhibition comprises two intravenous Alexion/Astrazeneca juggernauts, Soliris and Ultomiris. And another branch of the alternative pathway ...

Article found on: www.evaluate.com